• <a fr-original-style="" href="https://amp.ft.com/content/30070969-71bc-4ef9-a035-45d589b6fefe" rel="noopener noreferrer" style="color: rgb(9, 9, 9); text-decoration: none; background-color: transparent; outline: none; cursor: pointer; transition: color 0.3s ease 0s; touch-action: manipulation; user-select: auto; box-sizing: border-box;" target="_blank">GlaxoSmithKline</a> (GSK) has rejected a £50 billion (€60bn) offer from Unilever for its consumer goods arm, a joint division with Pfizer that produces household drugs like Theraflu and Otrivine, saying that it “fundamentally undervalued” the business and its potential.<ul fr-original-style="padding-inline-start: 20px;" style="padding-inline-start: 20px; margin-top: 0px; margin-bottom: 1em; list-style-position: inside; box-sizing: border-box;"><li fr-original-style="" style="box-sizing: border-box;">Behind the scenes: GSK’s consumer goods business is due to be spun out into a separate listing in the middle of the year, while Unilever’s stock has fallen 10% over the past year compared with Reckitt’s 1.4% and an 18% rise in Procter &amp; Gamble.</li></ul>

Otrivine ile ilgili hikayeler